<DOC>
	<DOCNO>NCT03029858</DOCNO>
	<brief_summary>The study investigate whether PD-L1 immuno-markers influenced osimertinib treatment advance epidermal growth factor receptor （EGFR）T790M positive advance NSCLC patient . In addition , explore whether PD-L1 immuno-markers predict safety efficacy subsequent use immune checkpoint inhibitor time PD due osimertinib resistance .</brief_summary>
	<brief_title>PD-L1 Other Immuno-markers Influenced Osimertinib Treatment Advanced NSCLC Patients</brief_title>
	<detailed_description>Investigate whether PD-L1 immuno-markers influence osimertinib treatment advance EGFR T790M positive advance NSCLC patient . explore whether PD-L1 immuno-markers predict safety efficacy subsequent use immune checkpoint inhibitor time PD due osimertinib resistance .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>1 . The patient enrol ASTRIS patient eligible ASTRIS study . 2 . The patient willing provide inform consent form provide specimen osimertinib treatment time PD . 3 . Patients must able undergo fresh tumor biopsy screen provide available tumor sample take &lt; 2 month prior screen . 4 . Fine needle aspirate specimen acceptable . 5 . Specimens metastatic bone lesion typically unacceptable unless confirm soft tissue component . 6 . The tumor specimen submit establish eligibility sufficient quantity allow PDL1 IHC biomarker analysis ( applicable ) prefer formalinfixed paraffin embed block . 1 . The patient sufficient tumor tissue specimen available detection . 2 . The Patient unwilling use exist data medical practice scientific research . 3 . The patient receive immunotherapy therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>